Literature DB >> 14722705

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.

Raymond F Anton1, David J Drobes, Konstantin Voronin, Ramon Durazo-Avizu, Darlene Moak.   

Abstract

BACKGROUND: This clinical laboratory study evaluated how the timing of drinking and subjective responses to alcohol are effected by the opioid antagonist naltrexone.
METHODS: Forty non-treatment seeking alcoholics were randomly assigned to treatment with 50 mg naltrexone or matching placebo for 7 days. On day 7, they were administered an "initial drink" of alcohol (blood alcohol levels of between 20 and 30 mg%) in a bar-like setting. In a random fashion, half of the subjects in each group (naltrexone and placebo) had either immediate or delayed (40 min) access to up to 8 additional mini-drinks over a 2-h period. In the delayed group subjective reactions to alcohol were measured prior to access to more drinks.
RESULTS: In the immediate access condition, subjects had similar drinking patterns, irrespective of whether they were taking naltrexone or placebo. However, in the delayed condition, naltrexone-treated subjects consumed fewer drinks and had a slower progression of drinking. There was a positive relationship between alcohol-induced stimulation and the number of drinks consumed in the placebo subjects but a negative correlation in the naltrexone subjects.
CONCLUSIONS: These data suggest that the effectiveness of naltrexone on alcohol consumption may be somewhat dependent on pattern of consumption. Since naltrexone seems to disrupt the connection between alcohol-induced stimulation and further alcohol consumption, there may be a time-critical period between drinks necessary for alcoholics to benefit from its effects. These findings are consistent with clinical trial data that suggest a potential synergistic effect between relapse prevention therapies and opiate antagonist pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722705     DOI: 10.1007/s00213-003-1720-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

2.  Alcohol dependence syndrome: measurement and validation.

Authors:  H A Skinner; B A Allen
Journal:  J Abnorm Psychol       Date:  1982-06

3.  Haloperidol reduces stimulant and reinforcing effects of ethanol in social drinkers.

Authors:  J L Enggasser; H de Wit
Journal:  Alcohol Clin Exp Res       Date:  2001-10       Impact factor: 3.455

4.  Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.

Authors:  Markus Gastpar; Udo Bonnet; Jobst Böning; Karl Mann; Lutz G Schmidt; Michael Soyka; Tilman Wetterling; Volker Kielstein; Dominic Labriola; Robert Croop
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

5.  Naltrexone and alcohol dependence. Role of subject compliance.

Authors:  J R Volpicelli; K C Rhines; J S Rhines; L A Volpicelli; A I Alterman; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1997-08

6.  Non-specific effect of naltrexone on ethanol consumption in social drinkers.

Authors:  H de Wit; J Svenson; A York
Journal:  Psychopharmacology (Berl)       Date:  1999-09-01       Impact factor: 4.530

7.  Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.

Authors:  A C King; J R Volpicelli; A Frazer; C P O'Brien
Journal:  Psychopharmacology (Berl)       Date:  1997-01       Impact factor: 4.530

8.  Naltrexone-induced alterations in human ethanol intoxication.

Authors:  R M Swift; W Whelihan; O Kuznetsov; G Buongiorno; H Hsuing
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

9.  Naltrexone in the treatment of alcoholism: predicting response to naltrexone.

Authors:  J R Volpicelli; K L Clay; N T Watson; C P O'Brien
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

10.  A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.

Authors:  David J Drobes; Raymond F Anton; Suzanne E Thomas; Konstantin Voronin
Journal:  Neuropsychopharmacology       Date:  2002-10-30       Impact factor: 7.853

View more
  64 in total

1.  An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics.

Authors:  Suzanne E Thomas; Amy K Bacon; Patrick K Randall; Kathleen T Brady; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Authors:  Samuel R Chamberlain; Karin Mogg; Brendan P Bradley; Annelize Koch; Chris M Dodds; Wenli X Tao; Kay Maltby; Bhopinder Sarai; Antonella Napolitano; Duncan B Richards; Edward T Bullmore; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

Review 3.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 4.  Applications of schedule-induced polydipsia in rodents for the study of an excessive ethanol intake phenotype.

Authors:  Matthew M Ford
Journal:  Alcohol       Date:  2014-02-28       Impact factor: 2.405

5.  N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers.

Authors:  Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal
Journal:  Alcohol Clin Exp Res       Date:  2015-02-09       Impact factor: 3.455

6.  Is talk "cheap"? An initial investigation of the equivalence of alcohol purchase task performance for hypothetical and actual rewards.

Authors:  Michael T Amlung; John Acker; Monika K Stojek; James G Murphy; James MacKillop
Journal:  Alcohol Clin Exp Res       Date:  2011-10-21       Impact factor: 3.455

7.  Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-17       Impact factor: 5.176

8.  Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Authors:  Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

9.  Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Authors:  Joseph P Schacht; Raymond F Anton; Konstantin E Voronin; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

10.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.